Hybrid purifier removes host cell proteins during mAb bioprocessing, study shows
Researchers have shown that a hybrid purifier can remove host cell proteins during the downstream processing of monoclonal antibodies.
List view / Grid view
Researchers have shown that a hybrid purifier can remove host cell proteins during the downstream processing of monoclonal antibodies.
A new report has found that if COVID-19 biologics are approved, it could apply pressure to the global biomanufacturing capacity.
Dose contract manufacturing organisations (CMOs) had slow revenue growth in 2019, a trend continuing into 2020 that could impact the US.
On 6 August 2020, US President Donald Trump signed an executive order, dubbed ‘Buy American’, with the aim of increasing the production of essential medicines in the US for domestic use. Here, Victoria Rees discusses the order and what it means for drug manufacturers in the US and rest of…
This article describes how researchers stepped up metformin tablet production from a pilot scale coater to three industrial scale equipment lines.
As the race to develop a COVID-19 vaccine intensifies, nations are already ramping up production capacity on a scale never seen before – but what does this mean for manufacturers? Here, Rod Schregardus makes the case for advanced planning and scheduling techniques in new and existing facilities.
Reducing unnecessary regulatory burden relating to excipients is important for any pharmaceutical manufacturer. In this article, Sunil Kumar Nataraj, Bastiaan Dickhoff and Kalyan Janjanam discuss a rational basis for controlling and specifying conflicting excipient attributes to avoid potentially tedious and complex regulatory processes.
According to various associations, the UK could experience a high influx of counterfeit medicines if it leaves the EU without a deal.
Rodney Steel, Chief Executive of the BCMPA – the Association for Contract Manufacturing, Packing, Fulfilment and Logistics – discusses the continued important role of outsourcing in the pharmaceutical industry and how contract manufacturers and packers have responded to some of the latest challenges.
The impact of COVID-19 is wide-reaching with disruptions to supply chains likely to continue over the coming years. In this article, Dave Elder discusses the effect of the pandemic on the supply and demand of critical medicines and what this means for pharma supply chains.
High-potency drugs present numerous opportunities for improved drug selectivity, efficacy and safety profiles.
In this in-depth focus explore the implications of Trump's 'Buy American’ order for drug manufacturers, how researchers step-up metformin production from lab to industry scale and a discussion on how advanced planning could enable pharmaceutical production to be scaled up.
Specialised in aseptic and containment barrier Isolation technology systems, Telstar UK has seen increased demand for its products from all across the life sciences sector has grown significantly in the past few years.
A report found the rise in outsourcing, growing popularity of biologics and expanding acceptance of quality-by-design approaches would drive the market expansion.
Read articles on validating rapid microbial methods according to regulatory requirements and how solid-state NMR spectroscopy can be used to analyse pharmaceuticals in this in-depth focus.